Mitochondria targeting nano agents in cancer therapeutics (Review) Retraction in /10.3892/ol.2020.12101

Zhang,Xiao‑Ying; Zhang,Pei-Ying

doi:10.3892/ol.2016.5302

Mitochondria targeting nano agents in cancer therapeutics (Review)

Retraction in: /10.3892/ol.2020.12101

Authors:
- Xiao‑Ying Zhang
- Pei-Ying Zhang
View Affiliations

Affiliations: Nanjing University of Chinese Medicine, Information Institute, Nanjing, Jiangsu 221009, P.R. China, Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China
Published online on: October 21, 2016 https://doi.org/10.3892/ol.2016.5302
Pages: 4887-4890
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondria have emerged as noteworthy therapeutic targets as their physiological functions are often altered in pathological conditions such as cancer. The electronic databases of MEDLINE, EMBASE and PubMed were searched for recent studies reporting the importance of mitochondria targeting nanoagents in cancer therapeutics. The concluding remarks of the above papers mostly confirmed the growing potential of these novel nanoagents in the area of anticancer research. Furthermore, numerous studies demonstrated the immense potential of nanocarriers in delivering mitochondria‑acting compounds to their target site. Among the assemblage of nanomaterials, carbon nanotubes (CNTs) are becoming more prominent for drug delivery due to favorable attributes including their unique shape, which promotes cellular uptake, and large aspect ratio that facilitates conjugation of bioactive molecules on their surface. The present review focused on the current view of variable options available in mitochondria‑targeting anticancer therapeutics. It may be concluded that improvements are essential for its establishment as a gold standard therapeutic option especially in the clinical setting.

View Figures

View References

1	Xiong H, Du S, Ni J, Zhou J and Yao J: Mitochondria and nuclei dual-targeted heterogeneous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicin. Biomaterials. 94:70–83. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen H and Chan DC: Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases. Hum Mol Genet. 18(R2): R169–R176. 2009. View Article : Google Scholar : PubMed/NCBI
3	Schapira AH: Mitochondrial diseases. Lancet. 379:1825–1834. 2012. View Article : Google Scholar : PubMed/NCBI
4	Fulda S, Galluzzi L and Kroemer G: Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 9:447–464. 2010. View Article : Google Scholar : PubMed/NCBI
5	Wallace DC: Mitochondria and cancer. Nat Rev Cancer. 12:685–698. 2012. View Article : Google Scholar : PubMed/NCBI
6	Warburg O, Wind F and Negelein E: The metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927. View Article : Google Scholar : PubMed/NCBI
7	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
8	Galluzzi L, Larochette N, Zamzami N and Kroemer G: Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene. 25:4812–4830. 2006. View Article : Google Scholar : PubMed/NCBI
9	Mathew R, Karantza-Wadsworth V and White E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007. View Article : Google Scholar : PubMed/NCBI
10	Yousif LF, Stewart KM and Kelley SO: Targeting mitochondria with organelle-specific compounds: strategies and applications. ChemBioChem. 10:1939–1950. 2009. View Article : Google Scholar : PubMed/NCBI
11	Liberman EA, Topaly VP, Tsofina LM, Jasaitis AA and Skulachev VP: Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature. 222:1076–1078. 1969. View Article : Google Scholar : PubMed/NCBI
12	Murphy MP and Smith RA: Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 47:629–656. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ross MF, Kelso GF, Blaikie FH, James AM, Cochemé HM, Filipovska A, Da Ros T, Hurd TR, Smith RA and Murphy MP: Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc). 70:222–230. 2005. View Article : Google Scholar : PubMed/NCBI
14	Cortes LA, Castro L, Pesce B, Maya JD, Ferreira J, Castro- Castillo V, Parra E, Jara JA and López-Muñoz R: Novel gallate triphenylphosphonium derivatives with potent antichagasic activity. PLoS One. 10:e01368522015. View Article : Google Scholar : PubMed/NCBI
15	Gruber J, Fong S, Chen CB, Yoong S, Pastorin G, Schaffer S, Cheah I and Halliwell B: Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol Adv. 31:563–592. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kang BH, Plescia J, Song HY, Meli M, Colombo G, Beebe K, Scroggins B, Neckers L and Altieri DC: Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest. 119:454–464. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB, Stein GS, Languino LR and Altieri DC: Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res. 16:4779–4788. 2010. View Article : Google Scholar : PubMed/NCBI
18	Johnson LV, Walsh ML and Chen LB: Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci USA. 77:990–994. 1980. View Article : Google Scholar : PubMed/NCBI
19	Battigelli A, Russier J, Venturelli E, Fabbro C, Petronilli V, Bernardi P, Da Ros T, Prato M and Bianco A: Peptide-based carbon nanotubes for mitochondrial targeting. Nanoscale. 5:9110–9117. 2013. View Article : Google Scholar : PubMed/NCBI
20	Emanuelsson O, Nielsen H, Brunak S and von Heijne G: Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. J Mol Biol. 300:1005–1016. 2000. View Article : Google Scholar : PubMed/NCBI
21	Szeto HH: Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 8:E277–E283. 2006. View Article : Google Scholar : PubMed/NCBI
22	Jean SR, Ahmed M, Lei EK, Wisnovsky SP and Kelley SO: Peptide-mediated delivery of chemical probes and therapeutics to mitochondria. Acc Chem Res. 49:1893–1902. 2016. View Article : Google Scholar : PubMed/NCBI
23	Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751–760. 2007. View Article : Google Scholar : PubMed/NCBI
24	Iyer AK, Khaled G, Fang J and Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 11:812–818. 2006. View Article : Google Scholar : PubMed/NCBI
25	Pastorin G: Crucial functionalizations of carbon nanotubes for improved drug delivery: a valuable option? Pharm Res. 26:746–769. 2009. View Article : Google Scholar : PubMed/NCBI
26	Marrache S and Dhar S: Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci USA. 109:16288–16293. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R and Farokhzad OC: Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA. 107:17939–17944. 2010. View Article : Google Scholar : PubMed/NCBI
28	Yamada Y and Harashima H: Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev. 60:1439–1462. 2008. View Article : Google Scholar : PubMed/NCBI
29	DSouza GG, Rammohan R, Cheng SM, Torchilin VP and Weissig V: DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release. 92:189–197. 2003. View Article : Google Scholar : PubMed/NCBI
30	Zhou F, Xing D, Wu B, Wu S, Ou Z and Chen WR: New insights of transmembranal mechanism and subcellular localization of noncovalently modified single-walled carbon nanotubes. Nano Lett. 10:1677–1681. 2010. View Article : Google Scholar : PubMed/NCBI
31	Moon HK, Lee SH and Choi HC: In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS Nano. 3:3707–3713. 2009. View Article : Google Scholar : PubMed/NCBI
32	Ali-Boucetta H, Al-Jamal KT, Müller KH, Li S, Porter AE, Eddaoudi A, Prato M, Bianco A and Kostarelos K: Cellular uptake and cytotoxic impact of chemically functionalized and polymer-coated carbon nanotubes. Small. 7:3230–3238. 2011. View Article : Google Scholar : PubMed/NCBI
33	Mao H, Kawazoe N and Chen G: Uptake and intracellular distribution of collagen-functionalized single-walled carbon nanotubes. Biomaterials. 34:2472–2479. 2013. View Article : Google Scholar : PubMed/NCBI
34	Holt BD, Dahl KN and Islam MF: Cells take up and recover from protein-stabilized single-wall carbon nanotubes with two distinct rates. ACS Nano. 6:3481–3490. 2012. View Article : Google Scholar : PubMed/NCBI
35	Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, Vlasova II, Belikova NA, Yanamala N, Kapralov A, et al: Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat Nanotechnol. 5:354–359. 2010. View Article : Google Scholar : PubMed/NCBI
36	Chin SF, Baughman RH, Dalton AB, Dieckmann GR, Draper RK, Mikoryak C, Musselman IH, Poenitzsch VZ, Xie H and Pantano P: Amphiphilic helical peptide enhances the uptake of single-walled carbon nanotubes by living cells. Exp Biol Med (Maywood). 232:1236–1244. 2007. View Article : Google Scholar : PubMed/NCBI
37	Ali-Boucetta H, Nunes A, Sainz R, Herrero MA, Tian B, Prato M, Bianco A and Kostarelos K: Asbestos-like pathogenicity of long carbon nanotubes alleviated by chemical functionalization. Angew Chem Int Ed Engl. 52:2274–2278. 2013. View Article : Google Scholar : PubMed/NCBI
38	Wick P, Manser P, Limbach LK, Dettlaff-Weglikowska U, Krumeich F, Roth S, Stark WJ and Bruinink A: The degree and kind of agglomeration affect carbon nanotube cytotoxicity. Toxicol Lett. 168:121–131. 2007. View Article : Google Scholar : PubMed/NCBI
39	Yang ST, Wang X, Jia G, Gu Y, Wang T, Nie H, Ge C, Wang H and Liu Y: Long-term accumulation and low toxicity of single-walled carbon nanotubes in intravenously exposed mice. Toxicol Lett. 181:182–189. 2008. View Article : Google Scholar : PubMed/NCBI
40	Campagnolo L, Massimiani M, Palmieri G, Bernardini R, Sacchetti C, Bergamaschi A, Vecchione L, Magrini A, Bottini M and Pietroiusti A: Biodistribution and toxicity of pegylated single wall carbon nanotubes in pregnant mice. Part Fibre Toxicol. 10:212013. View Article : Google Scholar : PubMed/NCBI
41	Salvador-Morales C, Flahaut E, Sim E, Sloan J, Green ML and Sim RB: Complement activation and protein adsorption by carbon nanotubes. Mol Immunol. 43:193–201. 2006. View Article : Google Scholar : PubMed/NCBI